Home
Conditions
Flaviviridae Infections

Clinical trial condition

Flaviviridae Infections

Explore clinical trials studying Flaviviridae Infections. Study availability and eligibility vary by location and protocol.

2,143 public trials 76 recruiting studies

Refine in advanced search Browse all conditions

Flaviviridae Infections trial results

Completed

Class II Invariant Chain HCV Vaccine Study

NCT03688061

Conditions: Blood-Borne Infections, Communicable Diseases, Digestive System Diseases, +8 more
Locations: Centre for Cinical Vaccinology and Tropical Medicine, Univeristy of Oxford Oxford, Oxfordshire, United Kingdom

Hepatology Clinical Trial Unit, John Radcliffe Hospital Oxford, Oxfordshire, United Kingdom

View Trial Details

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

NCT03067129

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +16 more
Locations: Univ of California San Francis /ID# 158002 San Francisco, California, United States

Childrens Hospital Colorado /ID# 157996 Aurora, Colorado, United States

CT Childrens Medical Ctr, US /ID# 158639 Hartford, Connecticut, United States

UF Hepatology Research at CTRB /ID# 158008 Gainesville, Florida, United States

View all 38 locations

View Trial Details

Completed

Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection

NCT03057847

Conditions: Blood-Borne Infections, Chemically-Induced Disorders, Chronic Disease, +20 more
Locations: Magee Womens Hospital of UPMC Pittsburgh, Pennsylvania, United States

View Trial Details

Completed

HCV RNA Fingerstick Assay as Useful Point of Care of Diagnostic Tool for Drug Users in Brussels

NCT04610762

Conditions: Blood-Borne Infections, Chemically-Induced Disorders, Chronic Disease, +18 more
Locations: CHU Saint-Pierre Brussels, Belgium

View Trial Details

Completed

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

NCT05108935

Conditions: Acquired Immunodeficiency Syndrome, Behavior, Blood-Borne Infections, +30 more
Locations: Duke Department of Population Health Sciences Durham, North Carolina, United States

NC Survivors Union Greensboro, North Carolina, United States

View Trial Details

Completed

Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics

NCT02596880

Conditions: Blood-Borne Infections, Cirrhosis, Communicable Diseases, +12 more
Locations: Shariati Hospital Tehran, Iran

View Trial Details

Completed

Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule

NCT00460486

Conditions: Arbovirus Infections, Brain Diseases, Central Nervous System Diseases, +17 more
Locations: Centrum Badan Farmakologii Klinicznej monipol Krakow, Poland

Niepubliczny ZOZ "Atarax" s.c. Olsztyn, Poland

Niepubliczny ZOZ "VITA" Olsztyn, Poland

"PANTAMED" Sp. z o.o. Olsztyn, Poland

View Trial Details

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT02219490

Conditions: Blood-Borne Infections, Chronic Disease, Chronic Hepatitis C Virus (HCV) Infection Genotype 1, +16 more
Locations: CHU Bab El Oued /ID# 145420 Algiers, Algeria

CHU Bologhine Hospital /ID# 145421 Algiers, Algeria

CHU Mustapha Bacha /ID# 132130 Algiers, Algeria

St Vincent's Hospital Sydney /ID# 131001 Darlinghurst, New South Wales, Australia

View all 187 locations

View Trial Details

Completed

Study on the Prevalence of Hepatitis C In a psychiatRic Population

NCT04600479

Conditions: Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +11 more
Locations: CHS de Blain Blain, France

CH Georges Daumézon Bouguenais, France

CHU Nantes Nantes, France

View Trial Details

Completed

Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area

NCT03008122

Conditions: Arbovirus Infections, Flaviviridae Infections, Flavivirus Infections, +6 more
Locations: Ponce School of Medicine CAIMED Center Ponce, Puerto Rico

View Trial Details

Flaviviridae Infections

Flaviviridae Infections trial results

Related conditions